News

BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...
Manufacturing issues at Novo facility disrupt Regeneron drug review
Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate ...
Regeneron Reports Second Quarter 2025 Financial and Operating Results
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Regeneron Earnings Call: Growth Amid Challenges
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results
Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.